

# MTN-008 Study-Specific Procedures Manual

## Table of Contents

---

### Section 1. Introduction

1.1	Sources of Procedural Information.....	1-1
1.2	Investigator Responsibilities .....	1-2
1.3	Study Activation Process.....	1-2
1.4	IRB/EC Submissions.....	1-2

### Section 2. Protocol

### Section 3. Documentation Requirements

3.1	Essential Documents .....	3-1
3.2	Participant Case History Documentation .....	3-2
	3.2.1 Case History Contents.....	3-2
	3.2.2 Source Data and Source Documentation.....	3-2
	3.2.3 Chart Notes.....	3-3
	3.2.4 Visit Checklists.....	3-4
	3.2.5 DataFax and Non-DataFax Forms Provided by MTN SDMC .....	3-4
	3.2.6 Document Organization .....	3-5
3.3	Study Product Accountability, Chain of Custody, and Dispensing Documentation .....	3-6
3.4	Record Retention Requirements.....	3-8

### Section 4. Participant Accrual

4.1	Study Accrual Plan and Site Accrual Targets .....	4-1
	4.1.1 Accrual Status Reporting.....	4-2
	4.1.2 Accrual Plan .....	4-2
4.2	Pre-Screening .....	4-2
4.3	Screening Administrative Procedures .....	4-2
	4.3.1 Site-Specific Eligibility SOP.....	4-3
	4.3.2 Screening Window .....	4-3
	4.3.3 Screening Procedures .....	4-4
	4.3.4 Screening for Pregnancy Cohort Participants.....	4-4
	4.3.5 Screening for Lactation Cohort Participants .....	4-5
	4.3.6 Screening and Enrollment Logs .....	4-6
4.4	Assignment of Participant ID Numbers .....	4-6
4.5	Enrollment .....	4-6
	4.5.1 Postponement of Enrollment .....	4-7
	4.5.2 Randomization .....	4-8
	4.5.3 Participant-Specific Procedures: Pregnancy Cohort .....	4-16
	4.5.4 Participant-Specific Procedures: Lactation Cohort .....	4-17
	4.5.5 PK Collection Procedures: Both Cohorts .....	4-17
4.6	Replacement of Unevaluable Participants.....	4-19
4.7	Product Use Instructions, First Product Use, and Adherence Counseling .....	4-20

## Section 5. Informed Consent

5.1	Overview of Informed Consent Requirements and Procedures .....	5-1
5.2	Informed Consent for Screening .....	5-2
5.3	Informed Consent for Enrollment .....	5-2
5.3.1	Informed Consent Support Materials .....	5-3
5.3.2	Comprehension Assessment.....	5-3
5.4	Informed Consent for Specimen Storage and Possible Future Research Testing .....	5-4
5.5	Additional Elements of the Informed Consent for MTN-008 .....	5-4
5.5.1	HIPAA.....	5-4
5.5.2	Certificate of Confidentiality.....	5-4
5.5.3	IRB Assessment of Risk and Impact on Consent Process.....	5-5
5.5.4	Site-specific Informed Consent Forms .....	5-5
5.5.5	Illiterate Participants.....	5-6
5.6	Documenting the Informed Consent Process .....	5-6

## Section 6. Participant Follow-up

6.1	Study Follow-up Plan and Participant Retention Targets .....	6-1
6.2	Types of Follow-up Visits .....	6-1
6.3	Location of Follow-up Visits .....	6-2
6.4	Follow-up Visit Scheduling.....	6-2
6.4.1	Target Visit Dates.....	6-2
6.4.2	Allowable Visit Windows .....	6-3
6.4.3	Missed Visits .....	6-3
6.5	Follow-up Visit Procedures.....	6-3
6.5.1	Mother and Infant Follow-up Procedures for Days 1 and 3 Phone Calls: Pregnant and Lactation Cohorts .....	6-3
6.6	Evaluable Participants .....	6-4
6.7	Day 6 Visit Procedures.....	6-5
6.7.1	Evaluations Prior to Initiation of Day 6 Visit Procedures .....	6-6
6.7.2	Day 6 Visit Procedures for Evaluable Participants .....	6-7
6.7.3	Abbreviated Day 6 Visit Procedures for Evaluable Participants for both Pregnancy and Lactation Cohorts.....	6-7
6.7.4	Day 6 Visit Procedures for Non-evaluable Participants for both Pregnancy Lactation Cohorts .....	6-8
6.8	Mother and Infant Follow-up Procedures for Day 14 Phone Call for both Pregnancy And Lactation Cohorts .....	6-9
6.9	Delivery Phone Call: Pregnancy Cohort Only .....	6-9
6.10	Delivery Visit: Pregnancy Cohort Only .....	6-9
6.11	Post-delivery Assessment: Pregnancy Cohort Only .....	6-10
6.12	Interim Visit: Pregnancy and Lactation Cohorts .....	6-10
6.13	Replacement of Unevaluable Participants: Both Cohorts .....	6-10
6.14	Procedures for Participants Who Discontinue Product .....	6-10
6.15	Premature Study Discontinuation for an Individual Participant.....	6-11

## Section 7. Visit Checklists

7.1	Use of Visit Checklists.....	7-1
-----	------------------------------	-----

7.2	Sequence of Procedures.....	7-2
-----	-----------------------------	-----

## **Section 8. Participant Retention**

8.1	Retention Definitions .....	8-1
8.2	Retention Requirements .....	8-2
8.3	Retention SOPs.....	8-2
8.4	Obtaining and Updating Locator Information.....	8-2
8.5	Retention Tips .....	8-3

## **Section 9. Study Product Considerations for Non-Pharmacy Staff**

9.1	Responsibilities and Obligations with Regard to Blinding .....	9-1
9.2	Study Product Regimens .....	9-3
9.3	Gel Use Instructions .....	9-4
9.4	Dispensing Study Products During On-Site Visits.....	9-4
9.5	Return of Unused Study Gel Supplies.....	9-4
9.6	Instructions for Insertion of Study Gel for the Participant .....	9-5

## **Section 10. Clinical Considerations**

10.1	Baseline Medical/Menstrual History and Ascertainment of Concomitant Medications For Maternal Participants .....	10-1
	10.1.1 Focused Medical/Menstrual History for Maternal Participants .....	10-1
	10.1.2 Initial Ascertainment of Concomitant Medications for Maternal Participants...	10-3
10.2	Medical History and Ascertainment of Concomitant Medications for Infant Participants .....	10-4
	10.2.1 Medical History Review for Infant Participants.....	10-5
	10.2.2 Ascertainment of Concomitant Medications for Infant Participants .....	10-5
10.3	Pre-existing Conditions for both Maternal and Infant Participants.....	10-5
10.4	Interval Medical/Menstrual History and Updating of Concomitant Medications Both for Maternal and Infant Participants .....	10-5
	10.4.1 Interval Medical/Menstrual History for Maternal Participants .....	10-6
	10.4.2 Interval Medical History for Infant Participants.....	10-6
	10.4.3 Updating Concomitant Medications Information Both for Maternal and Infant Participants.....	10-6
10.5	Physical Exams.....	10-7
	10.5.1 Abdominal Exam.....	10-7
	10.5.2 Breast Exam .....	10-7
10.6	Pelvic Exam.....	10-7
	10.6.1 Detailed Overview of Pelvic Exam .....	10-8
	10.6.2 Detailed Procedural Instructions .....	10-9
	10.6.3 Documentation of Pelvic Exam Findings.....	10-11
10.7	Genital Bleeding.....	10-13
	10.7.1 Genital Bleeding in Pregnancy Cohort Participants .....	10-13
	10.7.2 Genital Bleeding in Lactation Cohort Participants.....	10-13
	10.7.3 Participant Reports of Genital Bleeding/Genital Bleeding Assessment.....	10-13
	10.7.4 Clinician Assessment of Genital Bleeding .....	10-13
	10.7.5 Documentation of Genital Bleeding.....	10-14
10.8	STI/RTI Diagnosis and Treatment .....	10-15

10.9	Pre- and Post-Test HIV Counseling .....	10-15
10.10	Adverse Event Reporting Considerations .....	10-16
10.11	Urinary Tract Infections .....	10-16
10.12	Contraception Considerations .....	10-17
10.13	Pregnancy Considerations .....	10-17
10.14	Delivery Visit Procedures .....	10-18
10.15	Infant Procedures.....	10-18
10.15	Management of Laboratory Test Results.....	10-18
10.16	Clinical and Product Use Management .....	10-19

## **Section 11. Adverse Event Reporting and Safety Monitoring**

11.1	Definitions and General Reporting Guidance .....	11-1
11.1.1	Adverse Event (AE) .....	11-1
11.1.2	Serious Adverse Events (SAEs).....	11-2
11.1.3	Expedited Adverse Events (EAEs).....	11-2
11.1.4	Expedited Adverse Events (EAEs).....	11-2
11.2	Adverse Event Terminology .....	11-4
11.2.1	Maternal Adverse Event (AE) Reporting .....	11-5
11.2.2	Infant Adverse Event (AE) Reporting .....	11-8
11.3	Adverse Event Severity .....	11-9
11.4	Adverse Event Relationship to Study Product .....	11-9
11.5	Adverse Event Outcomes and Follow-Up Information.....	11-9
11.6	Reporting Recurrent Adverse Events .....	11-11
11.7	MTN-003 Safety Monitoring, Review, and Oversight.....	11-11
11.8	Safety Distributions from DAIDS .....	11-12
11.9	Mtn-008 Protocol Safety Review Team Plan.....	11-12
11.9.1	Roles and Responsibilities of the PSRT.....	11-12
11.9.2	PSRT Composition.....	11-13
11.9.3	Routine Safety Data Summary Reports; Content, Format, and Frequency ....	11-14
11.9.4	PSRT Communications .....	11-14

## **Section 12. Laboratory Considerations**

12.1	Overview and General Guidance.....	12-1
12.2	Specimen Labeling .....	12-2
12.3	Procedures for Specimens That Cannot be Evaluated.....	12-2
12.4	Use of LDMS .....	12-2
12.5	Urine Testing.....	12-4
12.5.1	Specimen Collection.....	12-5
12.5.2	Pregnancy Testing .....	12-5
12.5.3	Chlamydia and Gonorrhea Testing.....	12-5
12.6	Testing of Vaginal Specimens.....	12-5
12.6.1	Vaginal pH .....	12-5
12.6.2	Vaginal Fluid Wet Mount Testing.....	12-6
12.6.3	Rapid Test for Trichomoniasis .....	12-7
12.6.4	Vaginal Gram Stain .....	12-7
12.6.5	Papanicolaou (Pap) Test.....	12-8
12.6.6	HSV-2 Cultures .....	12-8

12.6.7	Chlamydia and Gonorrhea Testing in Cervical Swabs.....	12-8
12.6.8	Vaginal Swab for Quantitative Vaginal Flora Culture .....	12-9
12.6.9	Vaginal Swabs for Biomarker Analysis .....	12-10
12.6.10	Endocervical Swabs for Biomarker Analysis.....	12-10
12.7	Blood Testing .....	12-10
12.7.1	Specimen Collection and Initial Processing .....	12-10
12.7.2	Plasma Archive .....	12-11
12.7.3	HIV Testing.....	12-11
12.7.4	Hepatitis B Surface Antigen.....	12-11
12.7.5	Syphilis Testing.....	12-12
12.7.6	Blood Chemistries .....	12-12
12.7.7	Hematology Testing .....	12-12
12.7.8	Flow Cytometry for CD38 and HLA-DR.....	12-12
12.8	Testing for Tenofovir Levels.....	12-13
12.8.1	Tenofovir Levels in Blood .....	12-13
12.8.2	Tenofovir Levels in Cord Blood.....	12-14
12.8.3	Tenofovir Levels in Breast Milk .....	12-14
12.8.4	Shipping of Specimens of Tenofovir Levels .....	12-14

### Section 13. Behavioral Assessments

13.1	Overview .....	13-1
13.2	Equipment Requirements and Set-up .....	13-1
13.3	Keyboard and Mouse Use .....	13-2
13.4	Baseline Behavioral and Acceptability Questionnaire .....	13-2
13.5	Home Dosing Log .....	13-3
13.6	Follow-up Acceptability and Adherence Questionnaire.....	13-3
13.7	Gel Use Experience (GUE) Questionnaire.....	13-3
13.8	Hard Copy Back-up.....	13-4

### Section 14. Data Collection

14.1	DataFax Overview.....	14-1
14.2	DataFax Form Completion.....	14-2
14.2.1	Guidelines.....	14-2
14.2.2	How to Mark Response Boxes .....	14-3
14.2.3	How to Record Numbers.....	14-3
14.2.4	How to Record Dates .....	14-4
14.2.5	How to Record Time .....	14-5
14.2.6	Data Corrections and Additions .....	14-5
14.2.7	How to Handle Missing and Unknown Data.....	14-6
14.3	MTN-008 Study-Specific Data Collection Information.....	14-7
14.3.1	Participant ID numbers (PTIDs).....	14-7
14.3.2	Study Visit Timing .....	14-8
14.3.3	Visit Codes and Page Numbers .....	14-10
14.3.4	Staff Initials/Date .....	14-11
14.3.5	Case Report Form Completion Schedule .....	14-12
14.3.6	Site Review of DataFax Forms .....	14-17
14.3.7	Faxing DataFax Forms .....	14-18
14.3.8	Non-DataFax Forms .....	14-18
14.4	Form Supply and Storage.....	14-18

14.4.1	Form and Specimen Label Supply .....	14-18
14.4.2	Form Storage .....	14-19
14.5	Form Completion Instructions.....	14-19
14.6	Case Report Forms .....	14-20

## **Section 15. Data Communiqués**

## **Section 16. Study Reporting Plan**

16.1	Purpose of Reporting Plan.....	16-1
16.2	Study Reports .....	16-2
16.2.1	Data Quality Control (QC) Report .....	16-2
16.2.2	Clinical Data Quality Control (CQC) Queries .....	16-3
16.2.3	Site Specimen Repository Report.....	16-3
16.2.4	Summary Specimen Monitoring Report.....	16-3
16.2.5	Enrollment and Retention Report.....	16-3
16.2.6	Visit Adherence and Procedure Completion Report .....	16-3
16.2.7	Site Data Management Quality Report .....	16-3
16.2.8	Safety (PSRT) Reports .....	16-4
16.2.9	Network Lab Assay Results Report .....	16-4
16.2.10	Study Monitoring Committee (SMC) Report.....	16-4